Caroline Glatzel, Janik Fleißner, Theodhora Shuti, Valerie Glatzel, Tassilo Dege, Astrid Schmieder, Matthias Goebeler, Michael Sticherling, Andreas Kerstan
{"title":"Tildrakizumab长期治疗斑块型银屑病的有效性：一项超过76周的回顾性多中心分析","authors":"Caroline Glatzel, Janik Fleißner, Theodhora Shuti, Valerie Glatzel, Tassilo Dege, Astrid Schmieder, Matthias Goebeler, Michael Sticherling, Andreas Kerstan","doi":"10.1155/dth/6691386","DOIUrl":null,"url":null,"abstract":"<p><b>Background:</b> Psoriasis is a chronic inflammatory disease affecting skin and patients’ quality of life. Tildrakizumab is an IL-23p19-inhibitor approved for treatment of moderate-to-severe plaque psoriasis.</p><p><b>Objective:</b> To evaluate the effectiveness of tildrakizumab in daily practice in a heterogeneous cohort of patients with psoriasis often accompanied by comorbid (especially cardiometabolic) diseases.</p><p><b>Methods:</b> We conducted a retrospective analysis at two university outpatient clinics in Germany (April 2018 to June 2024), collecting data on patient characteristics, comorbidities, prior therapies, and treatment response.</p><p><b>Results:</b> The effectiveness analysis included 111 patients with psoriasis treated with tildrakizumab. Median PASI was 12.6 (IQR 11.0–18.6) at baseline and decreased to 6.0 (IQR 1.0–10.4) at Week 4, to 1.8 (IQR 1.0–10.4) at Week 16, and median PASI 0.00 (IQR 0.0–0.0) at Week 76. Median PASI < 3 was achieved by 64.6% at Week 16, 79.7% at Week 52 and 94.4% at Week 76 and PASI < 5 by 83.3% at Week 16, 94.2% at Week 52, and 100% at Week 76. The proportion achieving PASI75, PASI90, and PASI100 at Week 76 was 97.2%, 83.3%, and 58.3%. Patients with arterial hypertension (AHT) showed a lower PASI response compared to those without AHT, starting from Week 28 (<i>p</i> = 0.035) and continuing throughout the follow-up period. However, a detailed analysis indicates that patients with AHT also achieved PASI < 3 at Week 28 and beyond. Furthermore, patients with at least one cardiovascular risk factor (CRF: obesity, dyslipidemia, AHT, or type 2 diabetes mellitus, [46.8%]) demonstrated a less pronounced PASI response at Weeks 16, 28, and 64 compared to patients without such risk factors (<i>p</i><sub>wk16</sub> = 0.023; <i>p</i><sub>wk28</sub> = 0.012; <i>p</i><sub>wk64</sub> = 0.014). Median DLQI at baseline was 16.0 (IQR 9.5–22.0) and improved to 3.0 (IQR 1.0–8.0) at 4–16 weeks.</p><p><b>Conclusion:</b> This analysis confirmed effectiveness of tildrakizumab in a real-world setting, with notable improvements in PASI response observed in a heterogeneous patient cohort and a high level of quality of life improvement. It is noteworthy that patients with AHT and other CRF demonstrated lower treatment responses, indicating that these comorbidities may exert an influence on outcomes.</p>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/6691386","citationCount":"0","resultStr":"{\"title\":\"Effectiveness of Tildrakizumab in the Long-Term Treatment of Plaque Psoriasis: A Retrospective, Multicenter Analysis Over 76 Weeks\",\"authors\":\"Caroline Glatzel, Janik Fleißner, Theodhora Shuti, Valerie Glatzel, Tassilo Dege, Astrid Schmieder, Matthias Goebeler, Michael Sticherling, Andreas Kerstan\",\"doi\":\"10.1155/dth/6691386\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><b>Background:</b> Psoriasis is a chronic inflammatory disease affecting skin and patients’ quality of life. Tildrakizumab is an IL-23p19-inhibitor approved for treatment of moderate-to-severe plaque psoriasis.</p><p><b>Objective:</b> To evaluate the effectiveness of tildrakizumab in daily practice in a heterogeneous cohort of patients with psoriasis often accompanied by comorbid (especially cardiometabolic) diseases.</p><p><b>Methods:</b> We conducted a retrospective analysis at two university outpatient clinics in Germany (April 2018 to June 2024), collecting data on patient characteristics, comorbidities, prior therapies, and treatment response.</p><p><b>Results:</b> The effectiveness analysis included 111 patients with psoriasis treated with tildrakizumab. Median PASI was 12.6 (IQR 11.0–18.6) at baseline and decreased to 6.0 (IQR 1.0–10.4) at Week 4, to 1.8 (IQR 1.0–10.4) at Week 16, and median PASI 0.00 (IQR 0.0–0.0) at Week 76. Median PASI < 3 was achieved by 64.6% at Week 16, 79.7% at Week 52 and 94.4% at Week 76 and PASI < 5 by 83.3% at Week 16, 94.2% at Week 52, and 100% at Week 76. The proportion achieving PASI75, PASI90, and PASI100 at Week 76 was 97.2%, 83.3%, and 58.3%. Patients with arterial hypertension (AHT) showed a lower PASI response compared to those without AHT, starting from Week 28 (<i>p</i> = 0.035) and continuing throughout the follow-up period. However, a detailed analysis indicates that patients with AHT also achieved PASI < 3 at Week 28 and beyond. Furthermore, patients with at least one cardiovascular risk factor (CRF: obesity, dyslipidemia, AHT, or type 2 diabetes mellitus, [46.8%]) demonstrated a less pronounced PASI response at Weeks 16, 28, and 64 compared to patients without such risk factors (<i>p</i><sub>wk16</sub> = 0.023; <i>p</i><sub>wk28</sub> = 0.012; <i>p</i><sub>wk64</sub> = 0.014). Median DLQI at baseline was 16.0 (IQR 9.5–22.0) and improved to 3.0 (IQR 1.0–8.0) at 4–16 weeks.</p><p><b>Conclusion:</b> This analysis confirmed effectiveness of tildrakizumab in a real-world setting, with notable improvements in PASI response observed in a heterogeneous patient cohort and a high level of quality of life improvement. It is noteworthy that patients with AHT and other CRF demonstrated lower treatment responses, indicating that these comorbidities may exert an influence on outcomes.</p>\",\"PeriodicalId\":11045,\"journal\":{\"name\":\"Dermatologic Therapy\",\"volume\":\"2025 1\",\"pages\":\"\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-09-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/6691386\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dermatologic Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1155/dth/6691386\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatologic Therapy","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/dth/6691386","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
Effectiveness of Tildrakizumab in the Long-Term Treatment of Plaque Psoriasis: A Retrospective, Multicenter Analysis Over 76 Weeks
Background: Psoriasis is a chronic inflammatory disease affecting skin and patients’ quality of life. Tildrakizumab is an IL-23p19-inhibitor approved for treatment of moderate-to-severe plaque psoriasis.
Objective: To evaluate the effectiveness of tildrakizumab in daily practice in a heterogeneous cohort of patients with psoriasis often accompanied by comorbid (especially cardiometabolic) diseases.
Methods: We conducted a retrospective analysis at two university outpatient clinics in Germany (April 2018 to June 2024), collecting data on patient characteristics, comorbidities, prior therapies, and treatment response.
Results: The effectiveness analysis included 111 patients with psoriasis treated with tildrakizumab. Median PASI was 12.6 (IQR 11.0–18.6) at baseline and decreased to 6.0 (IQR 1.0–10.4) at Week 4, to 1.8 (IQR 1.0–10.4) at Week 16, and median PASI 0.00 (IQR 0.0–0.0) at Week 76. Median PASI < 3 was achieved by 64.6% at Week 16, 79.7% at Week 52 and 94.4% at Week 76 and PASI < 5 by 83.3% at Week 16, 94.2% at Week 52, and 100% at Week 76. The proportion achieving PASI75, PASI90, and PASI100 at Week 76 was 97.2%, 83.3%, and 58.3%. Patients with arterial hypertension (AHT) showed a lower PASI response compared to those without AHT, starting from Week 28 (p = 0.035) and continuing throughout the follow-up period. However, a detailed analysis indicates that patients with AHT also achieved PASI < 3 at Week 28 and beyond. Furthermore, patients with at least one cardiovascular risk factor (CRF: obesity, dyslipidemia, AHT, or type 2 diabetes mellitus, [46.8%]) demonstrated a less pronounced PASI response at Weeks 16, 28, and 64 compared to patients without such risk factors (pwk16 = 0.023; pwk28 = 0.012; pwk64 = 0.014). Median DLQI at baseline was 16.0 (IQR 9.5–22.0) and improved to 3.0 (IQR 1.0–8.0) at 4–16 weeks.
Conclusion: This analysis confirmed effectiveness of tildrakizumab in a real-world setting, with notable improvements in PASI response observed in a heterogeneous patient cohort and a high level of quality of life improvement. It is noteworthy that patients with AHT and other CRF demonstrated lower treatment responses, indicating that these comorbidities may exert an influence on outcomes.
期刊介绍：
Dermatologic Therapy has been created to fill an important void in the dermatologic literature: the lack of a readily available source of up-to-date information on the treatment of specific cutaneous diseases and the practical application of specific treatment modalities. Each issue of the journal consists of a series of scholarly review articles written by leaders in dermatology in which they describe, in very specific terms, how they treat particular cutaneous diseases and how they use specific therapeutic agents. The information contained in each issue is so practical and detailed that the reader should be able to directly apply various treatment approaches to daily clinical situations. Because of the specific and practical nature of this publication, Dermatologic Therapy not only serves as a readily available resource for the day-to-day treatment of patients, but also as an evolving therapeutic textbook for the treatment of dermatologic diseases.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
